CAR T therapy shows durable responses in large B-cell lymphoma

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

USC team develops analytical tool to advance CAR T-cell therapy research

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor T cells, including how they evolve during manufacturing and which ones are most effective at killing cancer.

May 02, 2025

Vol.51 No.17

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

May 02, 2025

Vol.51 No.17

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.

April 11, 2025

Vol.51 No.14

CAR T therapy shows durable responses in large B-cell lymphoma

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

USC team develops analytical tool to advance CAR T-cell therapy research

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login

CAR T therapy shows durable responses in large B-cell lymphoma

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

USC team develops analytical tool to advance CAR T-cell therapy research

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Never miss an issue!

Login

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child